<?xml version='1.0' encoding='utf-8'?>
<document id="27422590"><sentence text="Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study."><entity charOffset="36-48" id="DDI-PubMed.27422590.s1.e0" text="Rosuvastatin" /><entity charOffset="50-61" id="DDI-PubMed.27422590.s1.e1" text="Telmisartan" /><entity charOffset="67-77" id="DDI-PubMed.27422590.s1.e2" text="Amlodipine" /><pair ddi="false" e1="DDI-PubMed.27422590.s1.e0" e2="DDI-PubMed.27422590.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s1.e0" e2="DDI-PubMed.27422590.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s1.e0" e2="DDI-PubMed.27422590.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s1.e1" e2="DDI-PubMed.27422590.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s1.e1" e2="DDI-PubMed.27422590.s1.e2" /></sentence><sentence text="Rosuvastatin, a hydroxy methylglutaryl coenzyme A reductase inhibitor; telmisartan, an angiotensin receptor blocker; and amlodipine, a calcium channel inhibitor, are commonly prescribed together for the treatment of hypertension nonresponsive to monotherapy and accompanied by dyslipidemia"><entity charOffset="0-12" id="DDI-PubMed.27422590.s2.e0" text="Rosuvastatin" /><entity charOffset="71-82" id="DDI-PubMed.27422590.s2.e1" text="telmisartan" /><entity charOffset="87-98" id="DDI-PubMed.27422590.s2.e2" text="angiotensin" /><entity charOffset="121-131" id="DDI-PubMed.27422590.s2.e3" text="amlodipine" /><entity charOffset="135-142" id="DDI-PubMed.27422590.s2.e4" text="calcium" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e0" e2="DDI-PubMed.27422590.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e0" e2="DDI-PubMed.27422590.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e0" e2="DDI-PubMed.27422590.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e0" e2="DDI-PubMed.27422590.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e0" e2="DDI-PubMed.27422590.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e1" e2="DDI-PubMed.27422590.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e1" e2="DDI-PubMed.27422590.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e1" e2="DDI-PubMed.27422590.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e1" e2="DDI-PubMed.27422590.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e2" e2="DDI-PubMed.27422590.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e2" e2="DDI-PubMed.27422590.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e2" e2="DDI-PubMed.27422590.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e3" e2="DDI-PubMed.27422590.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s2.e3" e2="DDI-PubMed.27422590.s2.e4" /></sentence><sentence text=" However, the pharmacokinetic interactions among these 3 substances are not well understood" /><sentence text=" The aim of this study was to investigate the pharmacokinetic drug-drug interactions among rosuvastatin, telmisartan, and amlodipine in a healthy Korean male population"><entity charOffset="91-103" id="DDI-PubMed.27422590.s4.e0" text="rosuvastatin" /><entity charOffset="105-116" id="DDI-PubMed.27422590.s4.e1" text="telmisartan" /><entity charOffset="122-132" id="DDI-PubMed.27422590.s4.e2" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.27422590.s4.e0" e2="DDI-PubMed.27422590.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s4.e0" e2="DDI-PubMed.27422590.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s4.e0" e2="DDI-PubMed.27422590.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s4.e1" e2="DDI-PubMed.27422590.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s4.e1" e2="DDI-PubMed.27422590.s4.e2" /></sentence><sentence text="" /><sentence text="In both parts of this randomized, open-label, multiple-dose, 2-part, 2-period crossover study, subjects aged 19 to 55 years were enrolled" /><sentence text=" In part 1, each subject received rosuvastatin 20 mg with and without 2 fixed-dose combination (FDC) tablets of telmisartan/amlodipine 40/5 mg, once daily for 9 consecutive days"><entity charOffset="34-46" id="DDI-PubMed.27422590.s7.e0" text="rosuvastatin" /><entity charOffset="112-123" id="DDI-PubMed.27422590.s7.e1" text="telmisartan" /><entity charOffset="124-134" id="DDI-PubMed.27422590.s7.e2" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.27422590.s7.e0" e2="DDI-PubMed.27422590.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s7.e0" e2="DDI-PubMed.27422590.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s7.e0" e2="DDI-PubMed.27422590.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s7.e1" e2="DDI-PubMed.27422590.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s7.e1" e2="DDI-PubMed.27422590.s7.e2" /></sentence><sentence text=" In part 2, each subject received 2 FDC tablets of telmisartan/amlodipine 40/5 mg with and without rosuvastatin 20 mg, once daily for 9 consecutive days"><entity charOffset="51-62" id="DDI-PubMed.27422590.s8.e0" text="telmisartan" /><entity charOffset="63-73" id="DDI-PubMed.27422590.s8.e1" text="amlodipine" /><entity charOffset="99-111" id="DDI-PubMed.27422590.s8.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27422590.s8.e0" e2="DDI-PubMed.27422590.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s8.e0" e2="DDI-PubMed.27422590.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s8.e0" e2="DDI-PubMed.27422590.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s8.e1" e2="DDI-PubMed.27422590.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s8.e1" e2="DDI-PubMed.27422590.s8.e2" /></sentence><sentence text=" In both parts, there was a 13-day washout period between treatments" /><sentence text=" Pharmacokinetic samples were collected up to 72 hours after the last dose in subjects who received rosuvastatin only, and up to 144 hours after the last dose in subjects who received telmisartan/amlodipine with or without rosuvastatin"><entity charOffset="100-112" id="DDI-PubMed.27422590.s10.e0" text="rosuvastatin" /><entity charOffset="184-195" id="DDI-PubMed.27422590.s10.e1" text="telmisartan" /><entity charOffset="196-206" id="DDI-PubMed.27422590.s10.e2" text="amlodipine" /><entity charOffset="223-235" id="DDI-PubMed.27422590.s10.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e0" e2="DDI-PubMed.27422590.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e0" e2="DDI-PubMed.27422590.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e0" e2="DDI-PubMed.27422590.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e0" e2="DDI-PubMed.27422590.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e1" e2="DDI-PubMed.27422590.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e1" e2="DDI-PubMed.27422590.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e1" e2="DDI-PubMed.27422590.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e2" e2="DDI-PubMed.27422590.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s10.e2" e2="DDI-PubMed.27422590.s10.e3" /></sentence><sentence text=" Adverse events (AEs) were assessed via interviews and physical examinations" /><sentence text="" /><sentence text="Forty-eight subjects were enrolled, of whom 19 in part 1 and 22 in part 2 completed the study" /><sentence text=" In Part 1, the 90% CIs of the geometric mean ratios (GMRs) (coadministration of rosuvastatin and telmisartan/amlodipine to monotherapy with rosuvastatin) of the primary pharmacokinetic parameters (AUCÏ„ and Cmax,ss) were: rosuvastatin, 1"><entity charOffset="81-93" id="DDI-PubMed.27422590.s14.e0" text="rosuvastatin" /><entity charOffset="98-109" id="DDI-PubMed.27422590.s14.e1" text="telmisartan" /><entity charOffset="110-120" id="DDI-PubMed.27422590.s14.e2" text="amlodipine" /><entity charOffset="141-153" id="DDI-PubMed.27422590.s14.e3" text="rosuvastatin" /><entity charOffset="222-234" id="DDI-PubMed.27422590.s14.e4" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e0" e2="DDI-PubMed.27422590.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e0" e2="DDI-PubMed.27422590.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e0" e2="DDI-PubMed.27422590.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e0" e2="DDI-PubMed.27422590.s14.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e0" e2="DDI-PubMed.27422590.s14.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e1" e2="DDI-PubMed.27422590.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e1" e2="DDI-PubMed.27422590.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e1" e2="DDI-PubMed.27422590.s14.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e1" e2="DDI-PubMed.27422590.s14.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e2" e2="DDI-PubMed.27422590.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e2" e2="DDI-PubMed.27422590.s14.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e2" e2="DDI-PubMed.27422590.s14.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e3" e2="DDI-PubMed.27422590.s14.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s14.e3" e2="DDI-PubMed.27422590.s14.e4" /></sentence><sentence text="1436 to 1" /><sentence text="3059 and 1" /><sentence text="8970 to 2" /><sentence text="3514, respectively; and N-desmethyl rosuvastatin, 0"><entity charOffset="24-48" id="DDI-PubMed.27422590.s18.e0" text="N-desmethyl rosuvastatin" /></sentence><sentence text="8441 to 1" /><sentence text="0200 and 1" /><sentence text="1971 to 1" /><sentence text="5457" /><sentence text=" In part 2, the 90% CIs of the GMRs (coadministration to monotherapy with telmisartan/amlodipine) were: telmisartan, 1"><entity charOffset="74-85" id="DDI-PubMed.27422590.s23.e0" text="telmisartan" /><entity charOffset="86-96" id="DDI-PubMed.27422590.s23.e1" text="amlodipine" /><entity charOffset="104-115" id="DDI-PubMed.27422590.s23.e2" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.27422590.s23.e0" e2="DDI-PubMed.27422590.s23.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s23.e0" e2="DDI-PubMed.27422590.s23.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s23.e0" e2="DDI-PubMed.27422590.s23.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s23.e1" e2="DDI-PubMed.27422590.s23.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s23.e1" e2="DDI-PubMed.27422590.s23.e2" /></sentence><sentence text="1204 to 1" /><sentence text="4228 and 0" /><sentence text="9940 to 1" /><sentence text="5940; amlodipine, 0"><entity charOffset="6-16" id="DDI-PubMed.27422590.s27.e0" text="amlodipine" /></sentence><sentence text="9705 to 1" /><sentence text="0636 and 0" /><sentence text="9813 to 1" /><sentence text="0779" /><sentence text=" There were no significant differences in the prevalences of AEs between the treatments, and all reported AEs were mild or moderate" /><sentence text="" /><sentence text="These results demonstrate that when rosuvastatin, telmisartan, and amlodipine are coadministered to healthy male subjects, pharmacokinetic exposure increases with respect to rosuvastatin and telmisartan, whereas no change occurs with respect to amlodipine"><entity charOffset="36-48" id="DDI-PubMed.27422590.s34.e0" text="rosuvastatin" /><entity charOffset="50-61" id="DDI-PubMed.27422590.s34.e1" text="telmisartan" /><entity charOffset="67-77" id="DDI-PubMed.27422590.s34.e2" text="amlodipine" /><entity charOffset="174-186" id="DDI-PubMed.27422590.s34.e3" text="rosuvastatin" /><entity charOffset="191-202" id="DDI-PubMed.27422590.s34.e4" text="telmisartan" /><entity charOffset="245-255" id="DDI-PubMed.27422590.s34.e5" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e0" e2="DDI-PubMed.27422590.s34.e0" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e0" e2="DDI-PubMed.27422590.s34.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e0" e2="DDI-PubMed.27422590.s34.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e0" e2="DDI-PubMed.27422590.s34.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e0" e2="DDI-PubMed.27422590.s34.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e0" e2="DDI-PubMed.27422590.s34.e5" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e1" e2="DDI-PubMed.27422590.s34.e1" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e1" e2="DDI-PubMed.27422590.s34.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e1" e2="DDI-PubMed.27422590.s34.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e1" e2="DDI-PubMed.27422590.s34.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e1" e2="DDI-PubMed.27422590.s34.e5" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e2" e2="DDI-PubMed.27422590.s34.e2" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e2" e2="DDI-PubMed.27422590.s34.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e2" e2="DDI-PubMed.27422590.s34.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e2" e2="DDI-PubMed.27422590.s34.e5" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e3" e2="DDI-PubMed.27422590.s34.e3" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e3" e2="DDI-PubMed.27422590.s34.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e3" e2="DDI-PubMed.27422590.s34.e5" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e4" e2="DDI-PubMed.27422590.s34.e4" /><pair ddi="false" e1="DDI-PubMed.27422590.s34.e4" e2="DDI-PubMed.27422590.s34.e5" /></sentence><sentence text=" However, based on previous analyses, the degree of increase in the exposure observed was not regarded as clinically significant" /><sentence text=" All treatments were well-tolerated" /><sentence text="" /></document>